secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001171843-25-000089
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava cuts workforce 33% after Phase 3 miss; REFOCUS-ALZ results due Q1/Q2 2025
--------------------------------------------------------------------------------

- Workforce reduction of 10 employees (33%) with ~$0.4M severance costs in Q1 2025.
- Cash and cash equivalents ~$128.6M as of Dec 31, 2024 (unaudited).
- Topline data from Phase 3 REFOCUS-ALZ study expected late Q1/early Q2 2025.
- Halting planned biomarker analysis of additional plasma samples from prior Phase 2 studies.
- RETHINK-ALZ study did not meet co-primary endpoints; REFOCUS-ALZ and OLE study discontinued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/0001171843-25-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/f8k_010725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer